Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2018 | Multiple myeloma subgroups for risk-adapted therapy

Vittorio Montefusco • 19 Apr 2018
EMN 2018
Multiple Myeloma

The contemporary viewpoint is that multiple myeloma (MM) is a group of separate diseases, rather than just one type of cancer. This has allowed patients to be grouped according to their specific form of MM and receive treatment tailored to their subtype. In this video, recorded at the 1st European Myeloma Network Meeting (EMN) held in Turin, Italy, Vittorio Montefusco, MD, of the IRCCS Foundation, National Cancer Institute of Milan, Milan, Italy, describes some of the different subgroups of patients, how they are defined and what treatments are being developed for each of these groups.

More from Vittorio Montefusco

1:55
ASCT remains at the forefront of multiple myeloma therapy
Vittorio Montefusco • 19 Apr 2018

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals